Kyowa Kirin plans Japan pegfilgrastim filing on good Phase III data, but biosimilar G-CSFs loom
This article was originally published in Scrip
Kyowa Hakko Kirin plans to make a Japanese approval filing sometime this year for KRN125, its pegylated version of the granulocyte colony-stimulating factor (G-CSF) filgrastim, following positive top line results in two local Phase III trials.
You may also be interested in...
Join us for a brief audio tour around the past week's key developments in the global biopharma industry, in this podcast version of Scrip's Five Must-Know Things.
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.
Plus deals involving Takeda/OrigiMed, Amcure/Hinova, AUM/Newsoara, Taiho/Lung Therapeutics, 3D Medicines/Aravive, HitGen/Baiyunshan, Dong-A/Jiangsu Hengrui, and Crescita/Juyou.